Author

R. von Roemeling

Observed names: R V Roemeling, R von Roemeling, Reinhart von Roemeling, Richard Von Roemeling

Institution: Curis (United States)

Observed institutions: Johns Hopkins University, Moffitt Cancer Center, University of Alabama at Birmingham, Medizinische Hochschule Hannover, Curis (United States), Johns Hopkins Hospital, Daiichi Sankyo (United States)

OpenAlex ID: A5035172116

Circadian pattern of continuous FUDR infusion reduces toxicities.

1987 · R V Roemeling, W J Hrushesky · PubMed · 36

S129: Takeaim Leukemia- a Phase 1/2a Study of the Irak4 Inhibitor Emavusertib (ca-4948) as Monotherapy or in Combination With Azacitidine or Venetoclax in Relapsed/refractory Aml or Mds

2022 · G. Garcia-Manero, E. S. Winer, et al. · HemaSphere · 26

Met as Prognostic Factor and Therapeutic Target in Pretreated Hepatocellular Carcinoma (HCC): Final Results of a Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)

2012 · B. Daniele, L. Rimassa, et al. · Annals of Oncology · 5

Phase 1 Experience of Tivantinib in Patients with Hepatocellular Carcinoma (HCC) or Biliary Tract Cancer (BTC)

2012 · F. Chai, G. Abbadessa, et al. · Annals of Oncology · 4

Chemotherapie bei vorbehandeltem Morbus Hodgkin mit Lomustin, Bleomycin, Vinblastin und Dexamethason

2008 · J. Weiß, R. von Roemeling, et al. · DMW - Deutsche Medizinische Wochenschrift · 4

[Intestinal angiodysplasia in Von Willebrand-Jürgens syndrome causing massive gastrointestinal bleeding].

1980 · R von Roemeling, B Neidhardt, et al. · PubMed · 4

P1121: Takeaim Lymphoma- an Open-label, Dose Escalation and Expansion Trial of Emavusertib (ca-4948) in Combination With Ibrutinib in Patients With Relapsed or Refractory Hematologic Malignancies

2022 · E. Joffe, G. Nowakowski, et al. · HemaSphere · 3

Abstract CT311: A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC)

2014 · Ana B. Oton, Byoung Chul Cho, et al. · Cancer Research · 3

482 Relationship Between Tumor MET Expression and Clinical Outcomes in Cancer Patients Treated with Tivantinib

2012 · H. Zahir, S. Rodig, et al. · European Journal of Cancer · 2

87 A phase II trial of radiotherapy with concurrent tirapazamine, a hypoxic cytotoxin, for advanced head and neck carcinomas

1996 · Ding-Jen Lee, Andy Trotti, et al. · International Journal of Radiation Oncology*Biology*Physics · 2

An Open‐label Trial of Oral Ca‐4948 an Irak4 Inhibitor Combined With Ibrutinib in Adult Patients With Relapsed or Refractory Hematologic Malignancies

2021 · E. Joffe, R. Ramchandren, et al. · Hematological Oncology · 1

Therapiemöglichkeiten bei gastrointestinalen Lymphomen

1982 · G. Hartwich, H. J. König, et al. · Springer eBooks · 1

115 Tirapazamine plus cisplatin in patients (pts) with advanced non-small cell lung cancer (NSCLC)

1997 · K. Ng, V.A. Miller, et al. · Lung Cancer

[Anemias 3. Differential diagnosis].

1980 · H J König, R von Roemeling, et al. · PubMed

[Multiple neoplasms after arsenic therapy].

1979 · R von Roemeling, G Hartwich, et al. · PubMed

[Treatment of acute leukemia in adults with combination drug therapy of the TRAMPCO type].

1979 · G Hartwich, R von Roemeling, et al. · PubMed

[Anemias. 2. Differential diagnosis, normal values, diagnostic errors].

1979 · R von Roemeling, H J König, et al. · PubMed

[Anemia. 1. Classification].

1979 · H J König, R von Roemeling · PubMed

[Treatment results of therapy resistant acute leukemias with 7 cystostatic agents (TRAMPCO-scheme)].

1978 · G Hartwich, R von Roemeling, et al. · PubMed

Works count: 19

Citation count: 91

H-index: 4

I10-index: 2